Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model

Cancer Research

Volumn 62, Issue 5, 2002, Pages 1370-1376

  Raghow, Sharan ^a   Hooshdaran, Massoumeh Z ^a   Katiyar, Sanjay ^a   Steiner, Mitchell S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ESTRADIOL; FLUTAMIDE; PLACEBO; PROTEIN TAG; TESTOSTERONE; TOREMIFENE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; DISSECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; ESTRADIOL BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SEMINAL VESICLE; TESTOSTERONE BLOOD LEVEL; TISSUE LEVEL; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRADIOL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TESTOSTERONE; TOREMIFENE;

EID: 0036494569     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cancer statistics, 1999
2. Neoplastic transformation of the prostate
3. Chemoprevention of prostate cancer: Concepts and strategies
4. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention
5. Reversibility of prostatic intraepithelial neoplasia: Implications for chemoprevention
6. Prostatic intraepithelial neoplasia and endocrine manipulation
7. Prostatic intraepithelial neoplasia and endocrine manipulation
8. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17β-estradiol
9. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: Can estrogen treatment increase androgen receptor content?
10. Hormonal regulation of the androgen receptor expression in human prostatic cells in culture
11. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats
12. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats
13. Differential effects of diethylstilbestrol and estradiol-17β in combination with testosterone on rat prostate lobes
14. Rat estrogen receptor-α and -β and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats
15. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression
16. The induction of prostatic hypertrophy in the dog with androstanediol
17. The periurethral zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus
18. Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays
19. Developmental estrogenization of the prostate gland
20. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer
21. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
22. Cloning of a novel receptor expressed in rat prostate and ovary
23. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse
24. Comparative distribution of estrogen receptor-α (ER-α) and β (ER-β) mRNA in the rat pituitary, gonad, and reproductive tract
25. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
26. Androgens and estrogens: Their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate
27. Metastatic prostate cancer in a transgenic mouse
28. Androgen-independent prostate cancer progression in the TRAMP model
29. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats
30. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
31. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells
32. Review of the pharmacological properties of toremifene
33. Mechanism of lower genotoxicity of toremifene compared with tamoxifen
34. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model
35. Treatment of idiopathic oligozoospermia with tamoxifen: A randomized controlled study
36. Empirical medical therapy for male infertility
37. Nuclear receptor coactivators and corepressors
38. Generation and reproductive phenotypes of mice lacking estrogen receptor-β
39. Estrogen receptor-β: Implications for the prostate gland
40. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor-β
41. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
42. Role of estrogen signaling in prostatic hormonal carcinogenesis
43. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase
44. Inhibition of protein kinase C by tamoxifen
45. waf1/cip1